Join our experts as they dig deep into the latest global drug development trends, cultivating insight into the companies investing most heavily in R&D and uncovering which therapeutic areas are truly flourishing.
From early seeds of innovation to late‑stage successes, we’ll explore what’s taking root across the pipeline — and what’s set to bloom next.
Ian Lloyd
Senior Director of Pharmaprojects
View profile
Senior Director of Pharmaprojects
Citeline
Ian Lloyd is the Senior Director of Pharmaprojects and Data Integration, overseeing the content and analyst services for our drug development solution. He supports clients in their drug pipeline data requirements and inquiries, providing insight into the best search strategies to answer their drug related business questions and also identifying and analyzing trends in pharma R&D. For the past 32 years, he has authored the “Pharma Annual R&D Review” and its new active substances (NAS) launches supplement. This has become a must have industry report for those seeking to identify the changing fortunes of drug R&D. Ian joined Pharmaprojects in 1987, when it was part of PJB Publications. It was acquired by Informa in 2003, and spun out to form Citeline, now part of the Norstella group, in 2022. He previously worked in molecular biology as a research assistant at the University of Bristol.
Ian Lloyd is the Senior Director of Pharmaprojects and Data Integration, overseeing the content and analyst services for our drug development solution. He supports clients in their drug pipeline data requirements and inquiries, providing insight into the best search strategies to answer their drug related business questions and also identifying and analyzing trends in pharma R&D. For the past 32 years, he has authored the “Pharma Annual R&D Review” and its new active substances (NAS) launches supplement. This has become a must have industry report for those seeking to identify the changing fortunes of drug R&D. Ian joined Pharmaprojects in 1987, when it was part of PJB Publications. It was acquired by Informa in 2003, and spun out to form Citeline, now part of the Norstella group, in 2022. He previously worked in molecular biology as a research assistant at the University of Bristol.
Alex Shimmings
Executive Director, Europe Commercial
View profile
Executive Director, Europe Commercial
Citeline
Alex has held a variety of editorial positions of increasing seniority on Scrip since joining the publication as a science reporter in 1998. Currently, she heads up the European editorial team coverage of commercial and R&D developments, while also writing news, analysis and features. Over the years, Alex has covered breakthroughs in R&D in a range of therapeutic areas, including infectious diseases, cardiology and cancer, and she enjoys interviewing key industry players and opinion leaders. Alex has a degree in Biochemistry and Microbiology from the University of Leeds and a keen interest in medical history.
Alex has held a variety of editorial positions of increasing seniority on Scrip since joining the publication as a science reporter in 1998. Currently, she heads up the European editorial team coverage of commercial and R&D developments, while also writing news, analysis and features. Over the years, Alex has covered breakthroughs in R&D in a range of therapeutic areas, including infectious diseases, cardiology and cancer, and she enjoys interviewing key industry players and opinion leaders. Alex has a degree in Biochemistry and Microbiology from the University of Leeds and a keen interest in medical history.
